Pharmacological protection of DNA sequences that cap chromosomes might help treat inflammatory bowel disease (IBD), a study suggests. IBD is a chronic and disabling condition with limited therapeutic options. Past research has found that the intestinal cells of people with IBD have short telomeres, which are repetitive DNA sequences that are situated at the ends of chromosomes and offer protection from damage. Ronald DePinho and colleagues report that telomere erosion is not only a consequence of the inflammatory process but also drives intestinal inflammation. Analysis of intestinal biopsies from people with IBD revealed that telomere shortening is positively associated with disease severity and may underlie disease recurrence. In molecular studies, IBD intestinal organoids showed telomere-associated DNA damage and activation of the ATM/YAP1/pro-IL-18 signaling pathway, which promotes inflammation. The production of pro-IL-18, a cytokine that acts as a major driver of IBD, was reduced by pharmacological interventions that suppressed DNA damage, inhibited YAP1, or activated the telomerase enzyme, which catalyzes the addition of nucleotides to telomeres. In intestinal organoids from healthy individuals, the induction of telomere dysfunction led to DNA damage and activation of the ATM/YAP1/pro-IL-18 signaling pathway. Together, the findings suggest that telomere dysfunction instigates intestinal inflammation via DNA damage-mediated activation of the ATM/YAP1/pro-IL-18 pathway. According to the authors, the findings suggest potential therapeutic strategies for IBD.
Article #20-24853: "Telomere dysfunction instigates inflammation in inflammatory bowel disease," by Deepavali Chakravarti, Rumi Lee, et al.
MEDIA CONTACT: Ronald DePinho, University of Texas MD Anderson Cancer Center, Houston, TX; tel: 713-702-3215; e-mail: email@example.com
Proceedings of the National Academy of Sciences